Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-15
2005-11-15
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S295000, C514S440000, C514S554000, C514S565000, C514S578000, C514S579000, C514S690000, C514S733000, C514S738000, C514S762000, C424S752000
Reexamination Certificate
active
06964969
ABSTRACT:
A nutritional supplement composition for normalizing impaired or deteriorating neurological function in humans is composed of: at least one agent which promotes synthesis of ATP and/or creatine phosphate in the body, at least one antioxidant for scavenging free radicals in at least one pathway in the body; at least one agent for normalizing or maintaining membrane function and structure in the body; at least one agent for normalizing or maintaining normal neurotransmitter function in the body; at least one agent for down-regulating cortisol action; and at least one agent for suppressing activation of apoptotic pathways in the body. The composition may further contain one or more of: at least one agent for suppressing inflammation in the body; at least one agent for normalizing or maintaining vascular wall function and structure in the body; at least one agent for normalizing or maintaining function of nerve growth factors and/or neurotropic factors in the body; at least one agent for suppressing toxic metal ionic effects; at least one agent for normalizing or maintaining methyl metabolism in the body; at least one agent for normalizing or maintaining metabolism of insulin and glucose in the body; and at least one agent for up-regulating activity of heat shock proteins in the body. A method for normalizing impaired neurological function in humans modulating nutrient partitioning in a human involves administering the aforementioned composition to the human, preferably on a daily basis, for a therapeutically effective period of time. Preferably, the method further involves having the human follow a stress reduction program, and/or a cognitive retraining program, and/or a dietary program designed to maximize insulin and glucose metabolism.
REFERENCES:
patent: 4812447 (1989-03-01), Roberts
patent: 5104880 (1992-04-01), Kozikowski
patent: 5221668 (1993-06-01), Henningfield et al.
patent: 5668117 (1997-09-01), Shapiro
patent: 5716614 (1998-02-01), Katz et al.
patent: 6020139 (2000-02-01), Schwartz et al.
patent: 6063820 (2000-05-01), Cavazza
patent: 6117872 (2000-09-01), Maxwell et al.
patent: 401221316 (1989-09-01), None
patent: 410053256 (1998-02-01), None
Tarnopolsky MA, Beal MF. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol. May 2001; 49(5): 561-74.
Ferrante RJ, et al., Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci. Jun. 15, 2000; 20(12):4389-97.
Miller JW et al., Homocysteine, vitamin B6, and vascular disease in AD patients. Neurology. May 28, 2002; 58(10): 1471-5.
Dhitavat, S. et al.,Acety-L-carnitine protects against amyloid-beta neurotoxicity: roles of oxidative buffering and ATP levels. Neurochem Res. Jun. 2002; 27(6):501-5.
Liu J, et al., Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha-lipoic acid. Proc Natl Acad Sci USA. Feb. 19, 2002; 99(4):2356-61.
Gonzalez-Perez O, et al., Beneficial effects of alpha-lipoic acid plus vitamin E on neurological deficit, reactive gliosis and neural remodeling in the prenumbra of the ischemic rat brain. Neurosci Lett. Mar. 15, 2002: 321(1-2):100-4.
Baskaya MK, et al., Neuroprotective effects of citicholine on brain edema and blood-brain barrier breakdown after traumatic brain injury. J Neurosurg. Mar. 2000; 92(3):448-52.
Rao AM, et al., CDP-choline: neuroprotection in transient forebrain ischemia of gerbils. J Neurosci Res. Dec. 1, 1999; 58(5):697-705.
Claro FT, et al., Bovine brain phosphatidylserine attenuates scopolamine-induced amnesia. Physiol Behav. Oct. 1999; 67(4):51-4.
Chalon S, et al., Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. J Nutr. Dec. 1998; 128(12):2512-9.
Mischoulon D, Fava M., Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. AM J Clin Nutr. Nov. 2002: 76(5):1158S.
Genedanis S, et al., Influence of SAMe on the modifications of brain polyamine levels in an animal model of depression. Neuroreport. Dec. 21, 2001: 12(18):3939-42.
Pavia J, et al., Effect of S-adenosylmethionine on muscarinic receptors in young rats. Life Sci. 1997; 60(11):825-32.
McCarty MF., Prenatal high-dose pyridoxine may prevent hypertension and Syndrome X in-utero by protecting the fetus from excess glucocorticoid activity. Med Hypotheses. May 2000; 54(5):808-13.
Peng Ol, et al., Pycnogenol protects neurons from amyloid-beta peptide induced apoptosis. Brain Res Mol Brain Res. Jul. 15, 2002; 104(1):55-65.
Turkyilmaz C, et al. Magnesium pre-treatment reduces neuronal apoptosis in newborn rats in hypoxia-ischemia. Brain Res. Nov. 15, 2002; 955(1-2):133-7.
Wang MJ et al., Resveratrol inhibits interleukin-6 production in cortical mixed glial cells under hypoxia/hypoglycemia followed by reoxygenation. J Neuroimmunol. Jan. 1, 2001; 112(1-2):28-34.
Yang O et al., Protective effect of magnesium on the endothelial function mediated by endothelium-derived hyperpolarizing factor in coronary arteries during cardioplegic arrest in a porcine model. J Thoracic Cardiovasc Surgery. Aug. 2002; 124(2):361-70.
Murakami S et al., Taurine suppresses development of atherosclerosis in Watanabe heritable hyperlipidemic (WHHL) rabbits. Atherosclerosis. Jul. 2002; 163(1):79-87.
Pan Y et al., Evidence for up-regulation of brain-derived neurotrophic factor MRNA by soy phytosetrogens in the frontal cortex of retired breeder female rats. Neurosci Lett. Feb. 12, 1999; 261(1-2):17-20.
Brown JE et al., Structural dependence of flavonoid interactions with Cu2+ ions: implications for their antioxidant properties: Biochem J. Mar. 15, 1998; 330(pt.3):1173-8.
Niculescu, Mihai D. et al., Diet, Methyl Donors and DNA Methylation: Interactions between Dietary Folate, Methionine and Choline. American Society for Nutritional Sciences, Trans-HHS Workshop: Diet, DNA Methylation Processes and Health, 2002, pp. 2333S-2335S.
Ved HS et al., Huperzine A, a potential therapeutic agent for dementia, reduces neural cell death caused by glutamate. Neuroreport. Mar. 3, 1997; 8(4):963-8.
Martinez-Cruz F et al., Melatonin prevents focal rat cerebellum injury as assessed by induction of heat shock protein (HO-1) following subarachnoid injections of lysel blood. Neurosci Lett. Oct. 18, 2002; 331(3):208-10.
Vas, Adam et al., Clinical and non-clinical investigations using positron emission tomography, near infrared spectroscopy and transcranial Doppler methods on the neuroprotective drug vinpocetine: A summary of evidences. Journal of the Neurological Sciences 203-204,2002, pp. 259-262.
McIntosh III Traviss C.
Patton & Boggs LLP
Wilson James O.
LandOfFree
Composition and method for treating impaired or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for treating impaired or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for treating impaired or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3520689